Periodically we do updates on the iPS cell field and now seems like a good time. Where do things stand? Here’s my top 5 list of action items for the iPS cell field in the coming year. 5.) Methods on the brain. A significant fraction, some would argue too high a fraction, of iPS cell papers […]
Top 5 iPS cell action items Read More »
Periodically we do updates on the iPS cell field and now seems like a good time. Where do things stand? Here’s my top 5 list of action items for the iPS cell field in the coming year. 5.) Methods on the brain. A significant fraction, some would argue too high a fraction, of iPS cell
Key iPS cell action items Read More »
Recently I polled my readers on how they make iPS cells and what the best method is in their opinion. The surprising results to date are above. The first thing that is striking is how dominant the Yamanaka method remains after 5 years. Despite scads of papers reporting new methods that are supposedly better in
Striking results from iPS cell poll Read More »
What’s going on at ISSCR? A lot of cool stuff based on today’s Tweets from people attending. Tweeters are in ( ). Andras Nagy is the iPS cell Renaissance man! This morning at #ISSCR2011, talks by Shinya Yamanaka and Andras Nagy both featured Glis1, an egg-specific TF that promotes reprogramming. (the_Node) #ISSCR2011 Jaenisch:changing the order of
Top News from ISSCR today: exciting stuff! Read More »
Yamanaka may have found a way to give exogenous Myc the boot from the iPS cell universe. It has always been a frustration in the iPS cell field that Myc, a proto-oncogene, is so important for reprogramming. Yes, you can make iPS cells (especially mouse) without Myc, but it can be orders of magnitude harder,
New iPS cell method: drop Myc or not yet? Read More »
The best talk today was the keynote address by Dr. George Daley focused mostly on iPS cells. Dr. Daley is one of the world’s experts on iPS cells and pluripotent stem cells more generally. He covered many interesting elements of the iPS cell field including the genetic mutations that seem to occur during the reprogramming
Summary of George Daley talk on iPS cells today in Seattle Read More »
Yesterday I ran a cancer stem cells meeting here at UC Davis School of Medicine. We had some great speakers and over 150 participants including our outstanding keynote speaker, Dr. Jeremy Rich, Director of Stem Cell Research at the Cleveland Clinic. One of the ideas percolating through the meeting was that during cancer development, there
Cancer stem cells and iPS cells Read More »
Six months ago, I published a Top 10 list of questions and predictions for the stem cell field. How did I do? A mixed bag. Below are the questions and predictions from October 2010 (in blue), along with an update as to how my predictions fared. 1) How will Geron’s Phase I Clinical Trial go?
Stem Cell Questions & Predictions: how did I do? Read More »
How are things looking for the stem cell field for Spring 2011? Issue One. Getting to the clinic. At this point, Geron and ACT have their FDA-approved clinical trials underway using derivatives of human embryonic stem cells. As expected no news has leaked out on how things are going and it may well be Fall
Update on the stem cell field: Spring 2011 Read More »
Just how tumorigenic are iPS cells? The field really doesn’t know at this point. However, a steady stream of papers have raised red flag after red flag about genomic and epigenomic alterations/mutations that are linked to cancer. Of course, then there is the fact that all the genetic changes actually used to make reprogrammed cells
Secret Not so Secret Recipe for Safer iPS cells Read More »